- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07841847
Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease
Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease
This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Vural KAVUNCU, Prof. Dr.
- Número de teléfono: 90 505 777 43 06
- Correo electrónico: vural.kavuncu@ksbu.edu.tr
Copia de seguridad de contactos de estudio
- Nombre: Meltem ÇOBAN, Dr.
- Número de teléfono: +90 544 284 42 58
- Correo electrónico: meltem.368@hotmail.com
Ubicaciones de estudio
-
-
-
Kütahya, Turquía (Türkiye), 43020
- Kutahya Health Sciences University
-
Contacto:
- Vural KAVUNCU, Prof. Dr.
- Número de teléfono: 1111 02742630043
- Correo electrónico: vural.kavuncu@ksbu.edu.tr
-
Investigador principal:
- Fatima YAMAN, Assoc. Prof
-
Investigador principal:
- Meltem ÇOBAN, Dr.
-
Sub-Investigador:
- Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
-
Sub-Investigador:
- Mevlüt DEMİR, Assoc. Prof
-
Sub-Investigador:
- Cansu OZBAYER, Prof. Dr.
-
Sub-Investigador:
- Fatih KAR, Assoc. Prof.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Stable coronary artery disease
- History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Referred and considered clinically eligible for a structured cardiac rehabilitation program
- Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
- Ability and willingness to participate in the study and complete the cardiac rehabilitation program
Exclusion Criteria:
- Symptoms or signs of myocardial ischemia
- Significant left ventricular outflow tract obstruction
- Ventricular arrhythmia
- Significant valvular heart disease
- Uncontrolled hypertension
- Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
- Active malignancy
- Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
- Body mass index greater than 35 kg/m²
- History of orthopedic surgery within the previous 6 months
- Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
- Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
- Known psychiatric disorder
- Presence of a permanent cardiac pacemaker
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Personalized Cardiac Rehabilitation Group
Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program. |
Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in miRNA Expression Levels
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peak Oxygen Uptake (VO₂max)
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Exercise Workload
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Six-Minute Walk Test Distance
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Resting Heart Rate
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Heart Rate
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Health-Related Quality of Life
Periodo de tiempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- KSBÜ-CR-miRNA-
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .